Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome
Chemotherapy treatment of malignancy accounts for 1–2% of takotsubo syndrome (TS) triggers. Women comprise 60–70% of patients with chemotherapy-associated TS, a distinctly lower prevalence than the 90% female prevalence in TS overall. Fluorouracil is the most commonly reported TS-triggering chemothe...
Main Authors: | Katelyn Storey, Scott W Sharkey |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2020-02-01
|
Series: | US Cardiology Review |
Online Access: | https://www.uscjournal.com/articles/Chemotherapy-Induced-Takotsubo-Syndrome |
Similar Items
-
Super Recurrence of Takotsubo Syndrome: Clinical Characteristics and Late Cardiac Outcomes
by: Kirsten E. Shaw, et al.
Published: (2023-05-01) -
The challenge of Takotsubo syndrome: heterogeneity of clinical features
by: Susanne A. Schlossbauer, et al.
Published: (2017-10-01) -
Neurological Disorders in Takotsubo Syndrome: Clinical Phenotypes and Outcomes
by: Francesco Santoro, et al.
Published: (2024-02-01) -
Sclerotherapy Induced Takotsubo Syndrome
by: Sunny Patel, et al.
Published: (2020-01-01) -
Takotsubo syndrome as an acute cardiac complication following combined chemotherapy
by: H.A. Nati-Castillo, et al.
Published: (2024-09-01)